预测Gleason模式4存在的多模态生物标志物:对主动监测的潜在影响
研究在低危和中危前列腺癌患者中训练并独立验证了整合mRNA丰度、DNA甲基化和DNA拷贝数的多模态分类器PRONTO-e与PRONTO-m,用于区分病理分级分组1与≥2。在独立验证中,两分类器预测分级分组≥2的真阳性率分别为0.81和0.76,假阳性率分别为0.43和0.26,且识别出比CAPRA风险计算器更多的升级病例(P < .001)。
要点
- PRONTO-e由353个mRNA和拷贝数改变特征组成。
- PRONTO-m包含94个临床、mRNA、拷贝数改变和甲基化特征,分别位于14和12个位点。
- 两分类器对采样误差具有抵抗力,且比CAPRA识别出更多升级病例(P < .001)。
核心结论
- 通过整合RNA和DNA特征开发了两个准确性更优的分级分组分类器,并在独立队列中验证。
- 在活检样本中进一步验证后,具有这些性能特征的分类器可优化主动监测患者的选择,延长其无治疗生存期和监测间隔。
研究设计与样本
- 低危和中危前列腺癌患者被分配至训练队列(n=333)和验证队列(n=202)。
- 对每个肿瘤的2个位置检测342种mRNA的丰度、100个DNA拷贝数改变位点和14个高甲基化位点。
- 使用训练队列通过交叉验证评估在中心复核的前列腺根治术标本中训练病理分级分组≥2分类器的方法。
- 训练了PRONTO-e和PRONTO-m两个不同的分类器,并在独立的根治性前列腺切除队列中验证。
主要发现
- PRONTO-e由353个mRNA和拷贝数改变特征组成。
- PRONTO-m包含94个临床、mRNA、拷贝数改变和甲基化特征,分别位于14和12个位点。
- 在独立验证中,PRONTO-e预测分级分组≥2的真阳性率为0.81,假阳性率为0.43。
- 在独立验证中,PRONTO-m预测分级分组≥2的真阳性率为0.76,假阳性率为0.26。
- 两分类器对采样误差具有抵抗力,且比经过充分验证的术前风险计算器CAPRA(前列腺癌风险评估)识别出更多升级病例(P < .001)。
临床怎么用
- 在活检样本中进一步验证后,具有这些性能特征的分类器可优化主动监测患者的选择,延长其无治疗生存期和监测间隔。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Latent grade group ≥2 prostate cancer can impact the performance of active surveillance protocols. To date, molecular biomarkers for active surveillance have relied solely on RNA or protein. We trained and independently validated multimodal (mRNA abundance, DNA methylation, and/or DNA copy number) biomarkers that more accurately separate grade group 1 from grade group ≥2 cancers. MATERIALS AND METHODS: Low- and intermediate-risk prostate cancer patients were assigned to training (n=333) and validation (n=202) cohorts. We profiled the abundance of 342 mRNAs, 100 DNA copy number alteration loci, and 14 hypermethylation sites at 2 locations per tumor. Using the training cohort with cross-validation, we evaluated methods for training classifiers of pathological grade group ≥2 in centrally reviewed radical prostatectomies. We trained 2 distinct classifiers, PRONTO-e and PRONTO-m, and validated them in an independent radical prostatectomy cohort. RESULTS: PRONTO-e comprises 353 mRNA and copy number alteration features. PRONTO-m includes 94 clinical, mRNAs, copy number alterations, and methylation features at 14 and 12 loci, respectively. In independent validation, PRONTO-e and PRONTO-m predicted grade group ≥2 with respective true-positive rates of 0.81 and 0.76, and false-positive rates of 0.43 and 0.26. Both classifiers were resistant to sampling error and identified more upgrading cases than a well-validated presurgical risk calculator, CAPRA (Cancer of the Prostate Risk Assessment; P < .001). CONCLUSIONS: Two grade group classifiers with superior accuracy were developed by incorporating RNA and DNA features and validated in an independent cohort. Upon further validation in biopsy samples, classifiers with these performance characteristics could refine selection of men for active surveillance, extending their treatment-free survival and intervals between surveillance.
引用
- Berman DM, Lee AY, Lesurf R, et al. Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance. J Urol. 2023. PMID: 37126232. doi:10.1097/JU.0000000000003507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。